Risk of Bleeding Among Cangrelor-Treated Patients Administered Upstream P2Y₁₂ Inhibitor Therapy: The CAMEO Registry

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Limited data exists on bleeding risks of cangrelor in myocardial infarction (MI) patients pre-treated with oral P2Y12 inhibitors.
• Understanding this risk is crucial for optimizing antiplatelet therapy in acute MI management.

Purpose of the Study:

• To evaluate the bleeding risk associated with cangrelor administration in myocardial infarction (MI) patients who received prior oral P2Y12 inhibitor therapy.
• To compare bleeding outcomes between cangrelor-treated MI patients with and without upstream oral P2Y12 inhibitor exposure.

Main Methods:

• The Cangrelor in Acute MI: Effectiveness and Outcomes (CAMEO) registry prospectively collected data on MI patients treated with cangrelor.
• Upstream oral P2Y12 inhibition was defined as administration within 24 hours before hospitalization or before coronary angiography.
• Bleeding events were assessed up to 7 days post-discharge and compared between groups with and without upstream P2Y12 inhibitor exposure.

Main Results:

• Among 1802 cangrelor-treated MI patients, 21.4% had upstream oral P2Y12 inhibitor exposure.
• No statistically significant difference in bleeding rates was observed between patients with (6.5%) and without (8.8%) upstream exposure (adjusted OR, 0.62; 95% CI, 0.38-1.01).
• Bleeding rates also did not differ significantly based on the timing of cangrelor administration relative to the last oral P2Y12 inhibitor dose.

Conclusions:

• Cangrelor treatment in MI patients with or without prior oral P2Y12 inhibitor exposure is associated with comparable bleeding risks.
• The findings suggest that cangrelor can be safely used in this patient population without a significant increase in bleeding complications.